Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8330 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AZD8330 | DRUG | oral tablet |
Inclusion Criteria: * Cancer which is refractory to standard therapies, or no therapies exist; Exclusion Criteria: * Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start; * Hasn't participated in investigation drug study within 30 days; * Brain metastases/s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AZD8330 is an investigational small molecule being studied for the treatment of cancer. It is in Phase 1 clinical development, meaning it is still being tested in humans and has not been approved for any use.
AZD8330 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN.
AZD8330 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Its only clinical trial, a first-in-human study, has been completed.
AZD8330 has one completed clinical trial, identified as NCT00454090, titled "AZD8330 First Time in Man in Patients With Advanced Malignancies." This Phase 1 study enrolled 83 patients with cancer in the United States and Norway.
AZD8330 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it remains in clinical development and has not been authorized for marketing.